Authors: Allain, P Heudi, O Cailleux, A Le Bouil, A Larra, F Boisdron-Celle, M Gamelin, E

Citation: P. Allain et al., Early biotransformations of oxaliplatin after its intravenous administration to cancer patients, DRUG META D, 28(11), 2000, pp. 1379-1384

Authors: Gamelin, E Boissdron-Celle, M Guerin-Meyer, V Delva, R Lortholary, A Genevieve, F Larra, F Ifrah, N Robert, J

Citation: E. Gamelin et al., Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage, J CL ONCOL, 17(4), 1999, pp. 1105-1110

Authors: Dalifard, I Daver, A Larra, F

Citation: I. Dalifard et al., Cytosolic p53 protein and serum p53 autoantibody evaluation in breast cancer. Comparison with prognostic factors, ANTICANC R, 19(6B), 1999, pp. 5015-5022

Authors: Gosse-Brun, S Sauvaigo, S Daver, A Page, M Lortholary, A Larra, F Bignon, YJ Bernard-Gallon, D

Citation: S. Gosse-brun et al., Specific H-ras minisatellite alleles in breast cancer susceptibility, ANTICANC R, 19(6B), 1999, pp. 5191-5196